FDA approval of controversial Alzheimer's drug could delay discovery of more promising treatments
(Version anglaise seulement)
par Étienne Aumont, Étudiant au doctorat en psychologie, Université du Québec à Montréal (UQAM)
Marc-André Bédard, Professor of cognitive pharmacology, Université du Québec à Montréal (UQAM)
The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
Lire l'article complet
© La Conversation
-
mardi 15 juin 2021
